Cargando…

Development of a central nervous system axonal myelination assay for high throughput screening

BACKGROUND: Regeneration of new myelin is impaired in persistent multiple sclerosis (MS) lesions, leaving neurons unable to function properly and subject to further degeneration. Current MS therapies attempt to ameliorate autoimmune-mediated demyelination, but none directly promote the regeneration...

Descripción completa

Detalles Bibliográficos
Autores principales: Lariosa-Willingham, Karen D., Rosler, Elen S., Tung, Jay S., Dugas, Jason C., Collins, Tassie L., Leonoudakis, Dmitri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840960/
https://www.ncbi.nlm.nih.gov/pubmed/27103572
http://dx.doi.org/10.1186/s12868-016-0250-2
_version_ 1782428326574424064
author Lariosa-Willingham, Karen D.
Rosler, Elen S.
Tung, Jay S.
Dugas, Jason C.
Collins, Tassie L.
Leonoudakis, Dmitri
author_facet Lariosa-Willingham, Karen D.
Rosler, Elen S.
Tung, Jay S.
Dugas, Jason C.
Collins, Tassie L.
Leonoudakis, Dmitri
author_sort Lariosa-Willingham, Karen D.
collection PubMed
description BACKGROUND: Regeneration of new myelin is impaired in persistent multiple sclerosis (MS) lesions, leaving neurons unable to function properly and subject to further degeneration. Current MS therapies attempt to ameliorate autoimmune-mediated demyelination, but none directly promote the regeneration of lost and damaged myelin of the central nervous system (CNS). Development of new drugs that stimulate remyelination has been hampered by the inability to evaluate axonal myelination in a rapid CNS culture system. RESULTS: We established a high throughput cell-based assay to identify compounds that promote myelination. Culture methods were developed for initiating myelination in vitro using primary embryonic rat cortical cells. We developed an immunofluorescent phenotypic image analysis method to quantify the morphological alignment of myelin characteristic of the initiation of myelination. Using γ-secretase inhibitors as promoters of myelination, the optimal growth, time course and compound treatment conditions were established in a 96 well plate format. We have characterized the cortical myelination assay by evaluating the cellular composition of the cultures and expression of markers of differentiation over the time course of the assay. We have validated the assay scalability and consistency by screening the NIH clinical collection library of 727 compounds and identified ten compounds that promote myelination. Half maximal effective concentration (EC(50)) values for these compounds were determined to rank them according to potency. CONCLUSIONS: We have designed the first high capacity in vitro assay that assesses myelination of live axons. This assay will be ideal for screening large compound libraries to identify new drugs that stimulate myelination. Identification of agents capable of promoting the myelination of axons will likely lead to the development of new therapeutics for MS patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12868-016-0250-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4840960
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48409602016-04-23 Development of a central nervous system axonal myelination assay for high throughput screening Lariosa-Willingham, Karen D. Rosler, Elen S. Tung, Jay S. Dugas, Jason C. Collins, Tassie L. Leonoudakis, Dmitri BMC Neurosci Methodology Article BACKGROUND: Regeneration of new myelin is impaired in persistent multiple sclerosis (MS) lesions, leaving neurons unable to function properly and subject to further degeneration. Current MS therapies attempt to ameliorate autoimmune-mediated demyelination, but none directly promote the regeneration of lost and damaged myelin of the central nervous system (CNS). Development of new drugs that stimulate remyelination has been hampered by the inability to evaluate axonal myelination in a rapid CNS culture system. RESULTS: We established a high throughput cell-based assay to identify compounds that promote myelination. Culture methods were developed for initiating myelination in vitro using primary embryonic rat cortical cells. We developed an immunofluorescent phenotypic image analysis method to quantify the morphological alignment of myelin characteristic of the initiation of myelination. Using γ-secretase inhibitors as promoters of myelination, the optimal growth, time course and compound treatment conditions were established in a 96 well plate format. We have characterized the cortical myelination assay by evaluating the cellular composition of the cultures and expression of markers of differentiation over the time course of the assay. We have validated the assay scalability and consistency by screening the NIH clinical collection library of 727 compounds and identified ten compounds that promote myelination. Half maximal effective concentration (EC(50)) values for these compounds were determined to rank them according to potency. CONCLUSIONS: We have designed the first high capacity in vitro assay that assesses myelination of live axons. This assay will be ideal for screening large compound libraries to identify new drugs that stimulate myelination. Identification of agents capable of promoting the myelination of axons will likely lead to the development of new therapeutics for MS patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12868-016-0250-2) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-22 /pmc/articles/PMC4840960/ /pubmed/27103572 http://dx.doi.org/10.1186/s12868-016-0250-2 Text en © Lariosa-Willingham et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology Article
Lariosa-Willingham, Karen D.
Rosler, Elen S.
Tung, Jay S.
Dugas, Jason C.
Collins, Tassie L.
Leonoudakis, Dmitri
Development of a central nervous system axonal myelination assay for high throughput screening
title Development of a central nervous system axonal myelination assay for high throughput screening
title_full Development of a central nervous system axonal myelination assay for high throughput screening
title_fullStr Development of a central nervous system axonal myelination assay for high throughput screening
title_full_unstemmed Development of a central nervous system axonal myelination assay for high throughput screening
title_short Development of a central nervous system axonal myelination assay for high throughput screening
title_sort development of a central nervous system axonal myelination assay for high throughput screening
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840960/
https://www.ncbi.nlm.nih.gov/pubmed/27103572
http://dx.doi.org/10.1186/s12868-016-0250-2
work_keys_str_mv AT lariosawillinghamkarend developmentofacentralnervoussystemaxonalmyelinationassayforhighthroughputscreening
AT roslerelens developmentofacentralnervoussystemaxonalmyelinationassayforhighthroughputscreening
AT tungjays developmentofacentralnervoussystemaxonalmyelinationassayforhighthroughputscreening
AT dugasjasonc developmentofacentralnervoussystemaxonalmyelinationassayforhighthroughputscreening
AT collinstassiel developmentofacentralnervoussystemaxonalmyelinationassayforhighthroughputscreening
AT leonoudakisdmitri developmentofacentralnervoussystemaxonalmyelinationassayforhighthroughputscreening